



Lisa Zaba, MD, PhD

Clinical Associate Professor, Dermatology

CLINICAL OFFICES

- **Stanford Cancer Center South Bay**

2589 Samaritan Dr

San Jose, CA 95124

Tel (408) 426-4900

Fax (650) 721-3476

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Alesha Norton-Barnes - Administrative Associate

Email aleshan@stanford.edu

Bio

BIO

Lisa Zaba M.D. Ph.D., is Clinical Associate Professor of Dermatology and Director of the South Bay Cutaneous Oncology Program. She has a special interest in managing skin complications in cancer patients while they receive treatment including skin rashes, graft versus host disease, and skin cancer. She also has a special interest in rheumatologic diseases and autoimmunity that can be caused by some forms of immune based chemotherapeutics. At the South Bay Cancer Center (CCSB) she leads the multi-disciplinary melanoma clinic. Dr. Zaba completed medical school at Cornell University, PhD in immunology at Rockefeller University, Residency and Post-Doc at Stanford University in 2013.

CLINICAL FOCUS

- Dermatology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Dermatology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Director of Cutaneous Oncology at CCSB, Stanford, (2018- present)

HONORS AND AWARDS

- Research Scholar, New York Academy of Science (2002)
- Member, Alpha Omega Alpha, Weill Cornell Medical College (2003)
- Recipient, World Congress scholarship for Psoriasis research (2008)
- Recipient, Clinical Translational Science grant for Psoriasis research (2008)
- Intern of the Year, Memorial Sloan Kettering Cancer Center (2010)
- Recipient, National Dermatology Foundation Award for Scleroderma research (2013)

PROFESSIONAL EDUCATION

- Board Certification: Dermatology, American Board of Dermatology (2013)
- Residency: Stanford School of Medicine (2013) CA
- Internship: Memorial Sloan Kettering Cancer Center Transitional Year Training (2010) NY
- Medical Education: Weill Cornell Medical College (2009) NY

Publications

PUBLICATIONS

- **Increased Mortality in Black and Asian Patients with Systemic Sclerosis in Northern California**
Chung, M., Donsi, M., Postlethwaite, D., Kesh, S., Zaba, L., Chung, L.
WILEY.2018
- **Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.** *Cancer cell*
Qu, K., Zaba, L. C., Satpathy, A. T., Giresi, P. G., Li, R., Jin, Y., Armstrong, R., Jin, C., Schmitt, N., Rahbar, Z., Ueno, H., Greenleaf, W. J., Kim, et al
2017
- **Individuality and Variation of Personal Regulomes in Primary Human T Cells** *CELL SYSTEMS*
Qu, K., Zaba, L. C., Giresi, P. G., Li, R., Longmire, M., Kim, Y. H., Greenleaf, W. J., Chang, H. Y.
2015; 1 (1): 51-61
- **Individuality and variation of personal regulomes in primary human T cells.** *Cell systems*
Qu, K., Zaba, L. C., Giresi, P. G., Li, R., Longmire, M., Kim, Y. H., Greenleaf, W. J., Chang, H. Y.
2015; 1 (1): 51-61
- **Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1? antibodies in adults with dermatomyositis.** *Journal of the American Academy of Dermatology*
Fiorentino, D. F., Kuo, K., Chung, L., Zaba, L., Li, S., Casciola-Rosen, L.
2015; 72 (3): 449-455
- **Transposition of Native Chromatin for Fast and Sensitive Multitmodal Analysis of Chromatin Architecture**
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., Greenleaf, W. J.
CELL PRESS.2014: 77A
- **Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position** *NATURE METHODS*
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., Greenleaf, W. J.
2013; 10 (12): 1213-?
- **Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.** *Nature methods*
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., Greenleaf, W. J.
2013; 10 (12): 1213-1218
- **Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?.** *Arthritis and rheumatism*
Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., Mammen, A. L., Rosen, A., Casciola-Rosen, L.
2013; 65 (11): 2954-2962
- **Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?.** *Arthritis and rheumatism*
Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., Mammen, A. L., Rosen, A., Casciola-Rosen, L.
2013; 65 (11): 2954-2962
- **Skin disease in dermatomyositis** *CURRENT OPINION IN RHEUMATOLOGY*
Zaba, L. C., Fiorentino, D. F.
2012; 24 (6): 597-601